Dermtech Stock Analysis
| DMTK Stock | USD 0.62 0.02 3.33% |
DermTech is undervalued with Real Value of 1.73 and Target Price of 5.1. The main objective of DermTech stock analysis is to determine its intrinsic value, which is an estimate of what DermTech is worth, separate from its market price. There are two main types of DermTech's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect DermTech's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of DermTech's stock to identify patterns and trends that may indicate its future price movements.
The DermTech stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. DermTech is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. DermTech Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and DermTech's ongoing operational relationships across important fundamental and technical indicators.
DermTech |
DermTech Stock Analysis Notes
About 21.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.38. Some equities with similar Price to Book (P/B) outperform the market in the long run. DermTech recorded a loss per share of 3.09. The entity last dividend was issued on the 30th of August 2019. The firm had 1:2 split on the 30th of August 2019. DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. The company sells its products primarily to pathology and oncology practitioners. Dermtech operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 255 people. To learn more about DermTech call John MD at 858 450 4222 or check out https://www.dermtech.com.DermTech Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. DermTech's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding DermTech or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| DermTech generated a negative expected return over the last 90 days | |
| DermTech has high historical volatility and very poor performance | |
| DermTech has some characteristics of a very speculative penny stock | |
| DermTech has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 15.3 M. Net Loss for the year was (100.89 M) with profit before overhead, payroll, taxes, and interest of 647 K. | |
| DermTech currently holds about 173.79 M in cash with (76.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.78, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| DermTech has a frail financial position based on the latest SEC disclosures | |
| Latest headline from seekingalpha.com: DermTech exploring strategic alternatives, cutting 56 percent of staff |
DermTech Upcoming and Recent Events
Earnings reports are used by DermTech to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to DermTech previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
DermTech Largest EPS Surprises
Earnings surprises can significantly impact DermTech's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-08-04 | 2021-06-30 | -0.53 | -0.59 | -0.06 | 11 | ||
2020-05-13 | 2020-03-31 | -0.46 | -0.53 | -0.07 | 15 | ||
2021-03-04 | 2020-12-31 | -0.55 | -0.47 | 0.08 | 14 |
DermTech Thematic Classifications
In addition to having DermTech stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
 | HealthcareUSA Equities from Healthcare industry as classified by Fama & French |
DermTech Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as DermTech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading DermTech backward and forwards among themselves. DermTech's institutional investor refers to the entity that pools money to purchase DermTech's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Susquehanna International Group, Llp | 2023-12-31 | 85.7 K | Woodmont Investment Counsel Llc | 2023-12-31 | 84.2 K | Northern Trust Corp | 2023-12-31 | 77.5 K | Bank Of New York Mellon Corp | 2023-12-31 | 75.2 K | Jane Street Group, Llc | 2023-12-31 | 74.8 K | State Treasurer State Of Michigan | 2023-12-31 | 60 K | Advisor Group Holdings, Inc. | 2023-12-31 | 59.3 K | Marshall Wace Asset Management Ltd | 2023-12-31 | 57.6 K | Virtu Financial Llc | 2023-12-31 | 55.2 K | Vanguard Group Inc | 2023-12-31 | 1.4 M | Blackrock Inc | 2023-12-31 | 434.9 K |
DermTech Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 20.6 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate DermTech's market, we take the total number of its shares issued and multiply it by DermTech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.DermTech Profitablity
DermTech's profitability indicators refer to fundamental financial ratios that showcase DermTech's ability to generate income relative to its revenue or operating costs. If, let's say, DermTech is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, DermTech's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of DermTech's profitability requires more research than a typical breakdown of DermTech's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.83) | (0.87) | |
| Return On Capital Employed | (0.96) | (1.00) | |
| Return On Assets | (0.83) | (0.87) | |
| Return On Equity | (1.76) | (1.68) |
Management Efficiency
DermTech has return on total asset (ROA) of (0.3782) % which means that it has lost $0.3782 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0646) %, meaning that it created substantial loss on money invested by shareholders. DermTech's management efficiency ratios could be used to measure how well DermTech manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.87. The value of Return On Capital Employed is expected to slide to -1. At this time, DermTech's Total Current Liabilities is quite stable compared to the past year. Non Current Liabilities Total is expected to rise to about 53.9 M this year, although the value of Liabilities And Stockholders Equity will most likely fall to about 82 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.75 | 1.66 | |
| Net Current Asset Value | 0.00 | 0.00 | |
| Tangible Asset Value | 0.00 | 0.00 | |
| Tangible Book Value Per Share | 1.75 | 1.66 | |
| Enterprise Value Over EBITDA | (0.76) | (0.80) | |
| Price Book Value Ratio | 1.00 | 0.95 | |
| Enterprise Value Multiple | (0.76) | (0.80) | |
| Price Fair Value | 1.00 | 0.95 | |
| Enterprise Value | 28.1 M | 26.7 M |
The analysis of DermTech's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze DermTech's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of DermTech Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 2.558 |
Technical Drivers
As of the 30th of April, DermTech shows the Standard Deviation of 5.54, mean deviation of 3.76, and Variance of 30.69. DermTech technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate and analyze data for thirteen technical drivers for DermTech, which can be compared to its peers. Please confirm DermTech information ratio and skewness to decide if DermTech is priced favorably, providing market reflects its regular price of 0.62 per share. As DermTech is a penny stock we also recommend to verify its jensen alpha numbers.DermTech Price Movement Analysis
The output start index for this execution was twenty-eight with a total number of output elements of thirty-three. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. DermTech middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for DermTech. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
DermTech Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific DermTech insiders, such as employees or executives, is commonly permitted as long as it does not rely on DermTech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases DermTech insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Todd Wood over a month ago Acquisition by Todd Wood of 85114 shares of DermTech subject to Rule 16b-3 | ||
Sun Kevin M over a month ago Disposition of 445 shares by Sun Kevin M of DermTech at 0.7 subject to Rule 16b-3 | ||
Sun Kevin M over a month ago Disposition of 2531 shares by Sun Kevin M of DermTech at 0.88 subject to Rule 16b-3 | ||
Sun Kevin M over six months ago Sale by Sun Kevin M of 223 shares of DermTech | ||
Sun Kevin M over a year ago Sale by Sun Kevin M of 514 shares of DermTech | ||
Sun Kevin M over a year ago Sale by Sun Kevin M of 198 shares of DermTech |
DermTech Predictive Daily Indicators
DermTech intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of DermTech stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
DermTech Forecast Models
DermTech's time-series forecasting models are one of many DermTech's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary DermTech's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About DermTech Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how DermTech prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling DermTech shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as DermTech. By using and applying DermTech Stock analysis, traders can create a robust methodology for identifying DermTech entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (6.60) | (6.93) | |
| Operating Profit Margin | (6.78) | (7.12) | |
| Net Loss | (6.60) | (6.93) | |
| Gross Profit Margin | 0.02 | 0.03 |
Current DermTech Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. DermTech analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. DermTech analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 5.1 | Buy | 4 | Odds |
Most DermTech analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand DermTech stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of DermTech, talking to its executives and customers, or listening to DermTech conference calls.
DermTech Stock Analysis Indicators
DermTech stock analysis indicators help investors evaluate how DermTech stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading DermTech shares will generate the highest return on investment. By understating and applying DermTech stock analysis, traders can identify DermTech position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 77.8 M | |
| Common Stock Shares Outstanding | 32.6 M | |
| Total Stockholder Equity | 57.2 M | |
| Property Plant And Equipment Net | 56.7 M | |
| Cash And Short Term Investments | 55.9 M | |
| Cash | 36.7 M | |
| Accounts Payable | 1.5 M | |
| Net Debt | 17.7 M | |
| 50 Day M A | 0.7853 | |
| Total Current Liabilities | 13.4 M | |
| Other Operating Expenses | 119 M | |
| Non Current Assets Total | 60.2 M | |
| Non Currrent Assets Other | 3.5 M | |
| Stock Based Compensation | 18.6 M |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DermTech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy DermTech Stock please use our How to buy in DermTech Stock guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Complementary Tools for DermTech Stock analysis
When running DermTech's price analysis, check to measure DermTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DermTech is operating at the current time. Most of DermTech's value examination focuses on studying past and present price action to predict the probability of DermTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DermTech's price. Additionally, you may evaluate how the addition of DermTech to your portfolios can decrease your overall portfolio volatility.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |
Is DermTech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DermTech. If investors know DermTech will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DermTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.09) | Revenue Per Share 0.469 | Quarterly Revenue Growth 0.311 | Return On Assets (0.38) | Return On Equity (1.06) |
The market value of DermTech is measured differently than its book value, which is the value of DermTech that is recorded on the company's balance sheet. Investors also form their own opinion of DermTech's value that differs from its market value or its book value, called intrinsic value, which is DermTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DermTech's market value can be influenced by many factors that don't directly affect DermTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DermTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if DermTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DermTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.